Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

about

Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells Circulating biomarker panels for targeted therapy in brain tumors.Cytokines: The Good, the Bad, and the Deadly.

P2860

Q34645287-60A29101-E39C-4023-8F67-E2CA8531D746 Q38252948-9B362BAF-80A9-4ADC-B756-E583E5760D80 Q39002175-BCDB1601-97F7-48AD-BEC7-C4FA0B783949

P2860

Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

Item

http://www.wikidata.org/entity/Q36712746

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Cytokines associated with toxi ...... glioblastoma with aflibercept

@ast

Cytokines associated with toxi ...... glioblastoma with aflibercept

@en

type

Item

label

Cytokines associated with toxi ...... glioblastoma with aflibercept

@ast

Cytokines associated with toxi ...... glioblastoma with aflibercept

@en

prefLabel

Cytokines associated with toxi ...... glioblastoma with aflibercept

@ast

Cytokines associated with toxi ...... glioblastoma with aflibercept

@en

P1476

Cytokines associated with toxi ...... glioblastoma with aflibercept

@en

P2093

Alfred Yung

http://www.w3.org/2001/XMLSchema#string

Alice Chen

http://www.w3.org/2001/XMLSchema#string

Andrew B Lassman

http://www.w3.org/2001/XMLSchema#string

H Ian Robins

http://www.w3.org/2001/XMLSchema#string

John de Groot

http://www.w3.org/2001/XMLSchema#string

Jun Liu

http://www.w3.org/2001/XMLSchema#string

Mark Gilbert

http://www.w3.org/2001/XMLSchema#string

Michael Prados

http://www.w3.org/2001/XMLSchema#string

Nicole Shonka

http://www.w3.org/2001/XMLSchema#string

Patrick Y Wen

http://www.w3.org/2001/XMLSchema#string

P2860

IL-13 effector functions

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Molecular markers of radiation-related normal tissue toxicity.

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Mechanisms of cancer-related fatigue.

Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.

P2888

s11523-013-0254-0

P304

117-125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-013-0254-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lisa M DeAngelis

John V Heymach

P577

2013-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23345034

http://www.w3.org/2001/XMLSchema#string

P932

4802008

http://www.w3.org/2001/XMLSchema#string

Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

about

P2860

P2860

Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932